Equillium (EQ) EBITDA Margin (2023 - 2024)
Equillium (EQ) posted quarterly EBITDA Margin of 106.97% for Q4 2024, down 7223.0% year-over-year from 1.5% in Q1 2024, and down 1815.8% quarter-over-quarter from 5.58% in Q3 2024.
Equillium (EQ) EBITDA Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported EBITDA Margin for 2 consecutive years, with 106.97% the latest figure, recorded in Q4 2024.
- In Q4 2024, EBITDA Margin fell 7223.0% year-over-year to 106.97%; the TTM figure through Sep 2025 stood at 554.9% (down 54015.0% YoY), while the FY2024 annual figure was 20.12%, up 2012.0% from the prior year.
- EBITDA Margin slipped to 106.97% in Q4 2024 per EQ's latest filing, from 5.58% in the prior quarter.
- Across five years, EBITDA Margin topped out at 0.72% in Q2 2024 and bottomed at 106.97% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -106.97% |
| Sep 30, 2024 | -5.58% |
| Jun 30, 2024 | -0.72% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -34.74% |
| Sep 30, 2023 | -40.85% |
| Jun 30, 2023 | -39.36% |
| Mar 31, 2023 | -46.27% |